Search Results

There are 194273 results for: content related to: Benefits of treatment with rasagiline for fatigue symptoms in patients with early P arkinson's disease

  1. You have full text access to this OnlineOpen article
    A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

    European Journal of Neurology

    Volume 22, Issue 8, August 2015, Pages: 1184–1191, P. Barone, G. Santangelo, L. Morgante, M. Onofrj, G. Meco, G. Abbruzzese, U. Bonuccelli, G. Cossu, G. Pezzoli, P. Stanzione, L. Lopiano, A. Antonini and M. Tinazzi

    Version of Record online : 12 MAY 2015, DOI: 10.1111/ene.12724

  2. You have free access to this content
    Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease

    European Journal of Neurology

    Volume 20, Issue 1, January 2013, Pages: 5–15, J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli and W. H. Oertel

    Version of Record online : 22 DEC 2012, DOI: 10.1111/j.1468-1331.2012.03866.x

  3. Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease

    The Journal of Clinical Pharmacology

    Volume 45, Issue 8, August 2005, Pages: 878–894, Dr Jack J. Chen and Dr David M. Swope

    Version of Record online : 19 MAR 2013, DOI: 10.1177/0091270005277935

  4. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease

    European Journal of Neurology

    Volume 19, Issue 2, February 2012, Pages: 258–264, E. Tolosa and M. B. Stern

    Version of Record online : 5 AUG 2011, DOI: 10.1111/j.1468-1331.2011.03484.x

  5. The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

    The Journal of Clinical Pharmacology

    Volume 52, Issue 5, May 2012, Pages: 620–628, Dr Jack J. Chen and Dr Jayne R. Wilkinson

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011406279

  6. Monoamine Oxidase-B Inhibition in the Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 27, Issue 12P2, December 2007, Pages: 174S–185S, Dr. Hubert H. Fernandez and Dr. Jack J. Chen

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.27.12part2.174S

  7. Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline

    The Journal of Clinical Pharmacology

    Volume 50, Issue 12, December 2010, Pages: 1420–1428, Tamar Goren, Liat Adar, Nissim Sasson and Yoni M. Weiss

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010369674

  8. You have free access to this content
    Poster Presentations

    Movement Disorders

    Volume 27, Issue S1, June 2012, Pages: S1–S523,

    Version of Record online : 19 JUN 2012, DOI: 10.1002/mds.25051

  9. Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Rasagiline: A Potent, Selective, and Irreversible Monoamine Oxidase Type B Inhibitor

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 24, Issue 10, October 2004, Pages: 1295–1305, Dr. John J. Thébault, Dr. Michel Guillaume and Dr. Ruth Levy

    Version of Record online : 16 JAN 2012, DOI: 10.1592/phco.24.14.1295.43156

  10. Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

    Annals of the New York Academy of Sciences

    Volume 1122, Issue 1, December 2007, Pages: 155–168, ORLY WEINREB, TAMAR AMIT, ORIT BAR-AM and MOUSSA B.H. YOUDIM

    Version of Record online : 10 DEC 2007, DOI: 10.1196/annals.1403.011

  11. You have free access to this content
    The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline

    Journal of Neurochemistry

    Volume 112, Issue 5, March 2010, Pages: 1131–1137, Orit Bar-Am, Orly Weinreb, Tamar Amit and Moussa B. H. Youdim

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1471-4159.2009.06542.x

  12. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease

    International Journal of Clinical Practice

    Volume 60, Issue 2, February 2006, Pages: 215–221, F. Stocchi

    Version of Record online : 1 FEB 2006, DOI: 10.1111/j.1742-1241.2006.00806.x

  13. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

    Movement Disorders

    Volume 19, Issue 8, August 2004, Pages: 916–923, Matthew B. Stern, Kenneth L. Marek, Joseph Friedman, Robert A. Hauser, Peter A. LeWitt, Daniel Tarsy and C. Warren Olanow

    Version of Record online : 27 APR 2004, DOI: 10.1002/mds.20145

  14. Efficacy and tolerability of rasagiline in daily clinical use – a post-marketing observational study in patients with Parkinson’s disease

    European Journal of Neurology

    Volume 17, Issue 9, September 2010, Pages: 1164–1171, H. Reichmann and W. H. Jost

    Version of Record online : 17 MAR 2010, DOI: 10.1111/j.1468-1331.2010.02986.x

  15. Liquid chromatographic resolution of racemic rasagiline and its analogues on a chiral stationary phase based on (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid

    Journal of Separation Science

    Volume 36, Issue 23, December 2013, Pages: 3682–3687, Kyung Mi Tak, Eun Ju Park and Myung Ho Hyun

    Version of Record online : 9 OCT 2013, DOI: 10.1002/jssc.201300819

  16. A Validated Normal Phase LC Method for Enantiomeric Separation of Rasagiline Mesylate and Its (S)-Enantiomer on Cellulose Derivative-Based Chiral Stationary Phase

    Chirality

    Volume 25, Issue 6, June 2013, Pages: 324–327, P. Sunil Reddy, K. Sudhakar Babu and Navneet Kumar

    Version of Record online : 9 MAY 2013, DOI: 10.1002/chir.22150

  17. Is it possible to achieve bio-equivalence between an oral solid immediate-release and an analogue enteric-coated formulation?

    Journal of Pharmacy and Pharmacology

    Volume 68, Issue 10, October 2016, Pages: 1278–1289, Dannit Licht, Rachel Cohen, Ofer Spiegelstein, Laura Rabinovich-Guilatt, Marina Zholkovsky, Adrian Gilbert, Jennifer B. Dressman and Muhammad Safadi

    Version of Record online : 27 JUL 2016, DOI: 10.1111/jphp.12597

  18. Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

    Movement Disorders

    Volume 26, Issue 13, November 2011, Pages: 2316–2323, Peter Jenner and J. William Langston

    Version of Record online : 23 SEP 2011, DOI: 10.1002/mds.23926

  19. You have free access to this content
    Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration

    Journal of Neurochemistry

    Volume 105, Issue 5, June 2008, Pages: 1970–1978, Wen Zhu, Wenjie Xie, Tianhong Pan, Joseph Jankovic, Jun Li, Moussa B. H. Youdim and Weidong Le

    Version of Record online : 8 MAR 2008, DOI: 10.1111/j.1471-4159.2008.05330.x

  20. Serotonin Toxicity Association with Concomitant Antidepressants and Rasagiline Treatment: Retrospective Study (STACCATO)

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 34, Issue 12, December 2014, Pages: 1250–1258, Michel Panisset, Jack J. Chen, Sean H. Rhyee, Jill Conner, Julie Mathena and the STACCATO study investigators

    Version of Record online : 14 OCT 2014, DOI: 10.1002/phar.1500